Discovery and validation of sub-threshold genome-wide association study loci using epigenomic signatures

Xinchen Wang, Nathan R. Tucker, Gizem Rizki, Robert W. Mills, Peter H.l. Krijger, Elzo de Wit, Vidya Subramanian, Eric Bartell, Xinh-Xinh Nguyen, Jiangchuan Ye, Jordan Leyton‐Mange, Elena Dolmatova, Pim van der Harst, Wouter de Laat, Patrick T. Ellinor, Christopher Newton‐Cheh, David J. Milan, Manolis Kellis, Laurie A. BoyereLife 2016 · DOI

TL;DR

Genome-wide association studies (GWAS) often miss important genetic associations that fall below the strict statistical significance threshold. This paper shows how integrating epigenomic data (specifically, enhancer activity) with GWAS can effectively identify these "hidden" sub-threshold loci, revealing novel genes involved in cardiac function and providing a powerful new approach for complex trait genetics.

What Problem Does This Paper Address?

Genome-wide association studies (GWAS) are a powerful tool for identifying genetic variants associated with complex traits and diseases. However, a major challenge is that these studies often explain only a modest portion of the heritability. This is partly because many genetic variants have small effect sizes, requiring extremely large sample sizes to reach genome-wide statistical significance (typically a p-value < 5x10⁻⁸). Consequently, a vast number of genetic loci with p-values just below this threshold, termed "sub-threshold" loci, are often ignored. These sub-threshold loci may harbor important biological signals, but distinguishing true associations from false positives is difficult due to a high false positive rate. This paper aims to develop a method to systematically identify and validate these biologically relevant sub-threshold loci by leveraging epigenomic information.

Methods

The core of this study lies in integrating GWAS data with epigenomic maps, specifically focusing on enhancers.

  • Enhancer Annotation: The researchers utilized data from the Roadmap Epigenomics Project, which provides detailed maps of epigenomic marks (like H3K4me1 and H3K27ac) across various human tissues. These marks are indicative of active regulatory elements, particularly enhancers.
  • GWAS Data Integration: They compiled lists of single nucleotide polymorphisms (SNPs) associated with QT interval and QRS duration (traits related to heart electrical activity) from existing GWAS.
  • Enrichment Analysis: They systematically tested whether SNPs from GWAS loci (both above and below the significance threshold) were enriched in specific types of enhancers, particularly those active in cardiac tissues. This involved comparing the overlap of GWAS SNPs with enhancers against randomly selected genomic regions.
  • Sub-threshold Loci Prioritization: Based on the characteristics of enhancers that were enriched for known GWAS loci, they developed criteria to prioritize sub-threshold SNPs that were more likely to be biologically relevant. This involved looking for SNPs in enhancers with specific epigenomic marks (e.g., H3K27ac, DNase I hypersensitivity) and those showing evolutionary conservation.
  • Experimental Validation:
    • Luciferase Reporter Assays: They cloned predicted enhancer regions containing sub-threshold SNPs and tested their activity in human induced pluripotent stem cell (iPSC)-derived cardiomyocytes. This allowed them to assess if different alleles of a SNP could alter enhancer activity.
  • 4C-seq: This technique was used to investigate physical interactions between enhancers and gene promoters in cardiomyocytes, helping to identify potential target genes regulated by these enhancers.
  • Animal Models (Mouse and Zebrafish): Genetic perturbation of candidate genes identified through enhancer-gene linking was performed in mouse models to observe any resulting cardiac phenotypes. Zebrafish were used to study the effect of gene knockdown on cardiac electrical activity.

Datasets

  • Roadmap Epigenomics Project: This provided epigenomic data (histone modifications, DNase I hypersensitivity, CpG methylation) for 127 human tissues, including cardiac tissues.
  • Human Cardiomyocyte RNA-seq Dataset: RNA sequencing data from human iPSC-derived cardiomyocytes was used for gene expression analysis.
  • NHGRI GWAS Catalog: This served as the primary source for identified GWAS loci associated with QT interval and QRS duration.
  • Published GWAS Summary Statistics: Data from a meta-analysis of QT interval studies (Arking et al., 2014) was used for validation.
  • 1000 Genomes Project: Genotype data was used to identify SNPs in linkage disequilibrium (LD) with lead GWAS SNPs.
  • Mouse Phenotype Databases (MGI): Used to find documented phenotypes associated with genes linked to sub-threshold loci.

Key Insights and Ideas

  • Enhancers are Key Regulatory Hubs: The study strongly reinforces the idea that many disease-associated variants, even those with small effects, reside in regulatory elements like enhancers, rather than directly in protein-coding genes.
  • Epigenomic Signatures Discriminate Signal from Noise: Epigenomic maps, particularly those reflecting active enhancers in relevant tissues (like the heart), are powerful tools for filtering out false positives among sub-threshold GWAS signals.
  • Sub-threshold Loci are Biologically Relevant: The research provides compelling evidence that sub-threshold loci identified through epigenomic prioritization are not just statistical artifacts but represent genuine biological signals with functional consequences.
  • A New Paradigm for Discovery: This work offers a systematic approach to discover novel genes and pathways involved in complex traits, significantly expanding the scope of what can be identified from existing GWAS data without needing larger cohorts.

Key Results

  • Enrichment of Cardiac Enhancers: GWAS loci for QT interval and QRS duration showed significant enrichment in cardiac enhancers, particularly in the left ventricle.
  • Identification of Novel Sub-threshold Loci: By applying their epigenomic prioritization strategy, the researchers identified 2075 SNPs with p<1x10⁻⁴ that were independent of previously known loci. Of these, 208 overlapped with active LV enhancers.
  • Experimental Validation of Regulatory Activity: 13 out of 18 tested sub-threshold loci demonstrated allele-specific enhancer activity in human cardiomyocytes, indicating that the sub-threshold SNPs directly impact gene regulation.
  • Functional Link to Cardiac Phenotypes: Genetic perturbation of candidate genes linked to prioritized sub-threshold loci in mice resulted in cardiac conduction or contractility phenotypes, with a 4.11-fold enrichment compared to genes linked to all active LV enhancers.
  • Case Study: rs1743292/rs1772203 Locus: A detailed investigation of a specific sub-threshold locus revealed that SNPs within it disrupt enhancer activity, interact with the BVES gene promoter, and that BVES knockdown in zebrafish leads to ventricular repolarization defects, directly implicating this locus in QT interval regulation.

Limitations and Future Work

  • Tissue Specificity: While the study focused on cardiac enhancers, the generalizability to other tissues and traits relies on the availability of comprehensive epigenomic maps for those specific contexts.
  • Enhancer-Gene Linking: The method for linking enhancers to target genes, while improved by using cross-tissue expression patterns, is still an approximation and can be further refined.
  • Machine Learning Classifier: The authors suggest that a future direction is to build a machine learning classifier trained on above-threshold loci to quantitatively rank sub-threshold loci by predicted biological relevance.
  • Understanding "Winner's Curse": Further investigation is needed to understand the differences between above-threshold and sub-threshold loci, including whether weaker effect sizes in sub-threshold loci reflect different biological pathways or simply random chance in GWAS discovery.

Summary updated

Abstract

Genetic variants identified by genome-wide association studies explain only a modest proportion of heritability, suggesting that meaningful associations lie 'hidden' below current thresholds. Here, we integrate information from association studies with epigenomic maps to demonstrate that enhancers significantly overlap known loci associated with the cardiac QT interval and QRS duration. We apply functional criteria to identify loci associated with QT interval that do not meet genome-wide significance and are missed by existing studies. We demonstrate that these 'sub-threshold' signals represent novel loci, and that epigenomic maps are effective at discriminating true biological signals from noise. We experimentally validate the molecular, gene-regulatory, cellular and organismal phenotypes of these sub-threshold loci, demonstrating that most sub-threshold loci have regulatory consequences and that genetic perturbation of nearby genes causes cardiac phenotypes in mouse. Our work provides a general approach for improving the detection of novel loci associated with complex human traits.
BibTeX
@inproceedings{wang2016discovery,
  author = {Xinchen Wang and Nathan R. Tucker and Gizem Rizki and Robert W. Mills and Peter H.L. Krijger and Elzo de Wit and Vidya Subramanian and Eric Bartell and Xinh-Xinh Nguyen and Jiangchuan Ye and Jordan Leyton‐Mange and Elena Dolmatova and Pim van der Harst and Wouter de Laat and Patrick T. Ellinor and Christopher Newton‐Cheh and David J. Milan and Manolis Kellis and Laurie A. Boyer},
  title = {{Discovery and validation of sub-threshold genome-wide association study loci using epigenomic signatures}},
  booktitle = {eLife},
  year = {2016},
  doi = {10.7554/elife.10557},
}
Figure